Dr. Dahiya is a cancer specialist with board certification in internal medicine, hematology, and medical oncology. He is an Associate Professor at Stanford University School of Medicine and Clinical Director of Cancer Cell Therapy in the Stanford BMT and Cell Therapy division. Dr. Dahiya strives to support each patient with a personalized and compassionate care plan that optimizes healing and quality of life. Prior to joining Stanford, Dr. Dahiya was an associate professor of medicine at the Greenebaum Comprehensive Cancer Center at the University of Maryland School of Medicine, where he developed the Cellular Immunotherapy Program and served as the Director of Cellular Immunotherapy in leukemia and lymphoma. Dr. Dahiya’s research focuses on cellular immunotherapy for hematologic malignancies. He has led and participated in several investigator-initiated studies and sponsored clinical trials with cell therapies (CAR-T, CAR-NK, TCR-T) for hematologic malignancies. His research group is also involved in various translational research activities for the standard of care and research CAR-T therapy. Dr. Dahiya’s group was the first group to show the role of fibrinogen in Neurotoxicity associated with CAR-T therapy. They showed vascular injury as manifested by high fibrinogen levels is associated with higher Neurotoxicity in patients who receive CAR-T therapy. More recently his group led a novel study of assessing the immune response to COVID-19 disease. They evaluated the immune response in critically ill and non-critically ill patients hospitalized with COVID-19 disease and showed a differential immune response between the groups. Dr. Dahiya’s group also showed and established poor immunogenicity of COVID-19 vaccines in CART recipients. As such, passive immunity and other strategies to address the issues of immunogenicity are being explored. He has published more than 50 articles in peer-reviewed journals including the New England Journal of Medicine, Journal of Clinical Oncology, Blood, Blood Advances, Lancet, Leukemia Research, Neuro-Oncology, and many more. He reviews article submissions for the journals Critical Reviews in Oncology and Hematology, Thoracic Cancer, and Blood. He serves as the hematology lead editor for the journal Critical Reviews in Oncology and Hematology. He has presented his research findings at conferences such as the annual meetings of the American Society of Hematology, American Society of Clinical Oncology, and American Society for Transplantation and Cell Therapy. Dr. Dahiya is a member of the American Society of Hematology and the American Society of Transplantation and Cell Therapy.

Dr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR ) T therapy for patients with lymphomas and leukemias. Dr. Frank’s research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.

Dr. Hosoya is fellowship-trained in blood and marrow transplantation, cellular therapy and hematology with the Stanford Medicine Cancer Center and an instructor at Stanford University in the Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy. Her areas of expertise include transplantation, immunotherapies, and cellular therapies for patients with multiple myeloma and other plasma cell disorders. She diagnoses and treats a range of blood disorders from anemia and hemophilia to cancerous conditions like leukemia and multiple myeloma. For each patient, she prepares a personalized, comprehensive, and compassionate care plan. Dr. Hosoya’s research is focused on improving cancer diagnostics and therapeutic decision-making in multiple myeloma. She is specifically interested in the genomics of multiple myeloma and its evolution over the course of the disease. Dr. Hosoya is studying the role of circulating tumor DNA (ctDNA) in patients with multiple myeloma and developing tools to detect and quantify tumors and their response to chemotherapy and immunotherapy, with a goal of informing personalized therapies. Dr. Hosoya demonstrated ctDNA is useful in detecting and monitoring tumor, and its prognostic value for patients undergoing CAR T-cell therapy in multiple myeloma. Her ongoing research is focused on applying cell-free DNA sequencing towards sensitive detection of copy number alterations, gene expression inferences, and understanding mechanisms of disease response and resistance in diverse therapies in multiple myeloma. Dr. Hosoya is a member of the Society for Immunotherapy of Cancer, American Society of Clinical Oncology, American Society of Hematology, and the Japan Team Oncology Program.

Dr. Lekha Mikkilineni is a board-certified medical oncologist. She is also an Assistant Professor in the Department of Medicine, Division of Blood & Marrow Transplant and Cellular Therapy. Dr. Mikkilineni has extensive experience treating blood and bone marrow cancers. She currently provides care through the Bone Marrow Transplant & Cellular Therapy Program at Stanford Health Care. Her clinical focus is multiple myeloma, plasma-cell leukemia, Extramedullary myeloma, high-risk myeloma, CAR T cell therapy, bispecific therapy, amyloidosis, POEMS syndrome, and Waldenstrom’s macroglobunemia. Dr. Mikkilineni’s research centers on exploring novel CAR T-cell therapies to treat multiple myeloma and to define mechanisms of resistance to immunotherapy. She is particularly focused on understanding how to improve therapies for multiple myeloma patients who have extramedullary disease or high-risk features. Prior to coming to Stanford, she ran phase 1 CAR T-cell trials for multiple myeloma targeting BCMA and SLAMF7 at the National Cancer Institute. Dr. Mikkilineni received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research focusing on SLAMF7 as a potential target for multiple myeloma. She has received honors and awards for her work at the NCI. She has completed fellowships in hematology/oncology and immunotherapy at the National Heart, Lung, and Blood Institute/National Cancer Institute. She finished her residency in internal medicine at Thomas Jefferson University Hospital. She holds a Master of Science in medical sciences from Boston University and a medical degree from Tulane University. Dr. Mikkilineni has authored book chapters and published research in numerous high-impact academic journals. She has presented her findings through oral and poster presentations at national and international conferences.

Dr. Surbhi Sidana is an Associate Professor of Medicine at Stanford University and specializes in the treatment of multiple myeloma and related disorders. She leads the Myeloma CAR-T/Immunotherapy program at Stanford. Dr Sidana grew up in Delhi, India, where she completed her initial medical training. She then moved to the U.S and completed her Internal Medicine Residency at Cleveland Clinic in Cleveland, Ohio, followed by Hematology/Oncology fellowship at Mayo Clinic in Rochester, MN. Following this, she completed an Advanced Hematology Fellowship in Myeloma, Amyloidosis and Related Disorders at Mayo Clinic in Rochester, MN before joining Stanford University as a faculty member in 2019, where she has led the development of the myeloma CAR-T and bispecific antibody program. Dr Sidana has an active, broad research portfolio that includes clinical trials of novel therapies in myeloma and related disorders, translational research, epidemiologic and patient reported outcome studies. She has a special focus on research with immunotherapies such as CAR-T cell therapy and bispecific antibodies. She has published over 80 research manuscripts. Dr Sidana is the Leader of the Myeloma Disease Focused Group and the Associate Director for Clinical Research in the BMT and Cell Therapy Division at Stanford University. She also co-leads a multi-institutional collaboration on real world outcomes with immunotherapies in myeloma. Dr Sidana is actively involved in and holds leadership positions in national and international professional societies. She co-chairs the Quality-of-Life Committee of the International Myeloma Working Group and is the Vice-Chair of the American Society of Hematology Committee on Communications. She also a member of the ASH Editor Search Committee and the SWOG Myeloma Committee.

Dr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an assistant professor in the Department of Medicine in the Division of Blood & Marrow Transplantation and Cellular Therapy. She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, following her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. The research in her lab focuses on investigations of the biology of chimeric antigen receptor (CAR) T cells to improve the efficacy and safety of this therapy (1) by investigating donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by assessing mechanisms for the impact of the intestinal microbiome on CAR T cell response (Nature Medicine, 2022). Dr. Smith presents the findings of her research at regional, national, and international conferences. Further, she has co-authored articles on topics within the field of cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has appeared in journals, among others Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves a peer reviewer for publications in journals, such as NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She also has contributed to chapters in books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control. She has earned numerous honors; the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar. Dr. Smith is a member of the ASH Committee on Emerging Gene and Cell Therapies and the ASH Committee on Diversity, Equity & Inclusion. Additionally, she serves on committees within the institution and professional organizations focused on promoting diversity among hematology and cell therapy specialists.